Biomendex Oy is happy to inform that it has been selected as one of 10 start-up companies for a new Deep Tech Accelerator (DTA) program piloted by Business Finland.

Ambitious, cross-border research and innovation are constantly broadening our understanding of what is possible. For deep tech startups, the commercialization phase is usually much longer and riskier than for other companies, especially those working with medical devices. This is where Biomendex’s needs and Business Finland’s basic idea of

“This funding will strengthen Biomendex’s veterinary business expansion into new geographical market areas, as well as initiate new registration activities and amend the strategy for future clinical (human) orthopedic product launches. The first phase of the program is anticipated to last until the end of 2024” tells CEO Pasi Kankaanpää.

Topics: Adaptos, News, start-up